On Sept. 24, 2020, Novavax announced that it had initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, Novavaxﾒ COVID-19 vaccine candidate. The trial was conducted in the United Kingdom (UK), in partnership with the UK Governmentﾒs Vaccines Taskforce, and was expected to enroll and immunize up to 10,000 individuals between 18-84 (inclusive) years of age, with and without relevant comorbidities, over the next four to six weeks.